Lifeloc Reports Second Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Second Quarter 2026 Results WHEAT RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quart

Event · Earnings
Original reporting
Published Aug 14, 2026, 7:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 7:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LCTC
Neutral
medium confidence
Mentioned
$LCTC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LCTCNeutralMed
01

Why it matters

Traders can update expectations for near-term profitability (continued net losses) and medium-term product execution (SpinDetect beta testing and targeted limited commercial launch in Q1 2027).

02

Market read

The filing provides fresh quarterly financial datapoints (revenue, net loss, gross margin) and a concrete product timeline that can drive speculative positioning in an OTC name.

03

What to watch

SpinDetect beta and Q1 2027 limited launch are key catalysts, but the filing does not quantify commercialization traction, cash runway, or dilution risk beyond the $500K loan terms.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 14, 2026

Background

This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Lifeloc’s Q2 2026 operating results, product commentary, and a financing update.

Company-level read

Ticker impact

$LCTCNeutralMedium confidence
Context

Lifeloc reports Q2 2026 results with $2.445M revenue, a $134K net loss, and higher gross margin to 45% from 42% a year ago.

Expected impact

Likely modest, two-sided reaction: margin/revenue improvement is supportive, but loss level and financing terms may cap upside.

Evidence & confidence

The filing provides concrete quarterly financials and margin improvement, plus a financing update and a timeline for SpinDetect beta and limited launch in Q1 2027.

Market effects

Breath alcohol and drug testing device makers may see read-across interest in drug-analyzer platform progress and gross margin trajectory.

No clear regional macro linkage beyond a US-based OTC issuer.

Limited global relevance; story is company-specific with product and beta-testing milestones.

Counterpoint

Gross margin improvement may be partly mix/price-driven, while the company still burns cash and relies on asset-secured related-party financing.

Key entities

  • Lifeloc Technologies, Inc.

    OTC-listed developer and manufacturer of breath alcohol and drug testing devices; reports Q2 2026 financials and SpinDetect progress.

  • SpinDetect™ Centrifugal Drug Analyzer

    Oral-fluid drug analyzer platform; beta testing targeted for delta-9-THC and limited commercial launch targeted for Q1 2027.

  • Chairman/CFO loan

    $500,000 loan closed during the quarter, 10.5% interest with adjustable upward, interest-only in 2026, fully paid in 5 years, secured by all assets.

Related articles

$LCTCMed

Lifeloc Reports Third Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Third Quarter 2026 Results WHEAT RIDGE, Colo., November 16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quar

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.